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Abstract: This review deals with the relationship among nutrition, the immune system, and coronavirus
disease 2019 (COVID-19). The influence of nutrients and bioactive molecules present in foodstuffs on
immune system activity, the influence of COVID-19 on the nutritional status of the patients, and the
dietary recommendations for hospitalized patients are addressed. Deficient nutritional status is probably
due to anorexia, nausea, vomiting, diarrhea, hypoalbuminemia, hypermetabolism, and excessive nitrogen
loss. There is limited knowledge regarding the nutritional support during hospital stay of COVID-19
patients. However, nutritional therapy appears as first-line treatment and should be implemented into
standard practice. Optimal intake of all nutrients, mainly those playing crucial roles in immune system,
should be assured through a diverse and well-balanced diet. Nevertheless, in order to reduce the risk
and consequences of infections, the intakes for some micronutrients may exceed the recommended
dietary allowances since infections and other stressors can reduce micronutrient status. In the case of
critically ill patients, recently published guidelines are available for their nutritional management.
Further, several natural bioactive compounds interact with the angiotensin-converting enzyme
2 (ACE2) receptor, the gateway for severe acute respiratory syndrome (SARS) and severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Natural bioactive compounds can also reduce the
inflammatory response induced by SARS-CoV-2. These compounds are potential beneficial tools in
the nutritional management of COVID-19 patients.
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1. Introduction
In December 2019, there was an outbreak of pneumonia of unknown cause in Wuhan, Hubei
Province, China, which affected more than 60 people on the twentieth of that month. On 31 December,
the Wuhan Municipal Health Committee informed the World Health Organization (WHO) that 27
people had been diagnosed with pneumonia of unknown cause, being 7 of them critically ill [1].
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By January, the first cases of coronavirus disease 2019 (COVID-19) had been reported outside China:
two in Thailand and one in Japan. Then, the rapid spread of the disease prompted the WHO to
declare it as a health emergency of international concern, based on the impact the virus could have on
underdeveloped countries with fewer health infrastructure. By that date, the disease had been detected
in all provinces of mainland China, and cases were also diagnosed in 15 other countries. In March,
the disease was already in more than 100 territories worldwide, and recognized as a pandemic by the
WHO. At present, the number of confirmed cases continues to grow.
The virus that produced COVID-19 is the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), an enveloped positive-sense RNA virus that mainly affects the respiratory system,
being the spread of droplets generated by an infected subject the main route of transmission.
When SARS-CoV-2 binds angiotensin-converting enzyme 2 (ACE2) receptors in the alveolar
epithelial cells, the immune system responds through inflammation-related manifestation as well
as antigen-presenting cell recruitment (Figure 1). The disease can be asymptomatic or present mild
affection of the upper respiratory tract, while in the most severe cases is characterized by acute
respiratory distress syndrome, heart failure, and septic shock [2]. Moreover, as the disease advances,
multi-organ failure has also been reported as the result of uncontrolled acute inflammation. Indeed, the
immune response against the virus triggered by this uncontrolled inflammation results in pulmonary
tissue damage, which in turn reduces lung capacity. The tissue damage produced by SARS-CoV-2 at
the alveolar level is characterized by pathological changes of the tissue, infiltration, and hyperplasia.
Besides respiratory failure, other features have also been described as common in critically ill patients
of COVID-19, among them infiltration of immune cells into lung injuries, high levels of inflammatory
response, thrombosis, and multi-organ failure [3].
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angiotensin-converting enzyme 2 (ACE2) receptor to enter the host cell and the transmembrane
protease serine 2 (TMPRSS2) for Spike (S) protein priming.
iti the pres nce of other c ronic diseases in th patient may exacerbate the inflammatory
response deriv d from COVID-19, increasing the risk for adverse effects and mortali y. In this egard,
the systemic inflamma ion present in subjects with on-commun cable diseases (NCDs), such as
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diabetes, tend to make the respiratory symptoms of the infection more severe [4]. On the other hand, it
has been reported that excessive body mass index (BMI) and/or adiposity are considered risk factors
for complications derived from COVID-19 infection, especially in patients with compromised heart
and lung function [5]. Similarly, the damage in blood vessels that commonly exist in patients with
diabetes and/or high-blood pressure increases the risk of these subjects to suffer COVID-19 derived
thrombotic complications.
Due to the novelty of this pandemic, scientific community is currently looking for effective
vaccines, as well as drugs to treat the pathology. One of the biggest challenges is focused on reducing
inflammation, without compromising the correct immune response of the patient. In this scenario,
science should focus not only in effective drugs but also in nutrition. The importance of an adequate
nutritional status and dietary habits has been extensively highlighted in the COVID-19 pandemic,
not only as a matter of avoiding the presence of NCDs that can result in more severe infections, but
also as a way to modulate the inflammatory status of the patients. Indeed, the underestimation of the
importance of nutrition in COVID-19 patients can dramatically affect the outcome of these patients [3,6].
The aim of the present review is to analyze the current knowledge on the relationship among
nutrition, the immune system, and COVID-19 in order to formulate clinical advice and to highlight
the directions for future research. Thus, the influence of nutrients and bioactive molecules present in
foodstuffs on immune system activity, the influence of COVID-19 on nutritional status of patients and
the dietary recommendations for COVID-19 hospitalized patients are addressed in this manuscript.
2. The Role of Specific Dietary Nutrients on Immune System Function and COVID-19 Disease
The influence of nutrition in the immune system has been widely reported. In addition, recent
studies have also highlighted the influence of both, an adequate nutritional status and the appropriate
intake of specific nutrients in COVID-19. Nevertheless, due to the novelty of the disease, information
regarding the effects of some nutrients is scarce, and in some cases, this information comes from
ecological studies. Therefore, it seems plausible that part of the information included in this section
may be updated in the upcoming months as the result of the research that is currently ongoing. Protein
deficiency is linked to impaired immune system function, mainly due to its negative effects on both, the
amount of functional immunoglobulins and gut-associated lymphoid tissue (GALT). Besides quantity,
the quality of proteins is also an important factor with regard to the relationship of this macronutrient
with immune system. In this line, it has been highlighted that including proteins of high biological
value (those present in eggs, lean meat, fish, and dairy) containing all the essential amino acids may
exert an anti-inflammatory effect. In addition, some amino acids, such as arginine and glutamine are
well known for their ability to modulate the immune system [7].
Among lipids, the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) can inactivate enveloped viruses by modulating the optimal host lipid conditions for viral
replication. On the other hand, EPA and DHA inhibit cyclooxygenase enzymes (COX) and, thus, may
help suppressing prostaglandin (pro-inflammatory) production [3]. Moreover, they are enzymatically
converted to pro-resolving mediators (SPMs), such as protectins, resolvins, and maresins, alleviating
inflammation [8]. According to these effects, the supplementation with DHA and EPA may be useful to
reduce the severity and/or improve the recovery of patients with COVID-19. On the other hand, polar
lipids, such as phospholipids, glycolipids or sphingolipids (also present in food sources of omega 3
fatty acids, such as fish and fish oils) have the ability to block platelet-activating factor (PAF) as well
as its receptor, exerting anti-inflammatory effects that may be beneficial in COVID-19. Moreover, it
has also been described that these lipid species can also down-regulate the enzymes involved in PAF
biosynthesis, as well as up-regulate those involved on its degradation [9]. The blockage of platelet
activation may also be useful to prevent the thrombotic complications associated to COVID-19 [3].
Carbohydrates and dietary fiber have also been reported to be related to immune system function.
As far as carbohydrates is concerned, the consumption of those with higher glycemic indexes (highly
processed carbohydrates) can result in mitochondrial overload and subsequent free radical synthesis.
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Indeed, increased circulating levels of inflammatory cytokines such as C reactive protein (CRP), tumor
necrosis factor alpha (TNF-α), and interleukin-6 (IL-6) have been reported with the consumption of
these kind of carbohydrates [10]. Due to the aforementioned inflammatory status that usually occurs in
respiratory infections such as COVID-19, limiting the consumption of foods rich in these carbohydrates
may be advisable.
With regard to fiber, its importance for a correct metabolic functioning has been widely reported.
Several studies have revealed that an adequate fiber intake (25–35 g/day) may help reducing both,
systemic and gut inflammation. Indeed, the consumption of foods that are source of fiber has been
related to lower levels of inflammatory cytokines (CRP, TNF-α, and IL-6), as well as enhanced levels
of short chain fatty acids (SCFAs) [7]. In this regard, it has been described that different SCFAs
(acetate, propionate, and butyrate) have a direct anti-inflammatory effect by inhibiting the release of
pro-inflammatory molecules and by decreasing the expression of nuclear factor kB (NF-kB). Moreover,
SCFAs also play an important role in the maintenance of an adequate gut microbiota by increasing
the diversity, as well as enhancing the presence of specific health-associated bacteria [11]. Besides
gut microbiota, nasopharyngeal microbiota may also be involved in respiratory infections. Indeed,
it has been reported that this kind of infections may result in altered gut microbiota and innate
immune system response [12]. Taking into account that COVID-19 has been related to respiratory and
gastrointestinal symptoms, it seems plausible that gut microbiota impairment may occur, which in
turn can result in an enhanced inflammatory status.
Vitamins A, C, D, E, B6, B12, and folate, iron, magnesium and trace elements including zinc,
selenium and copper [13,14] play a pivotal role in disease susceptibility and the maintenance of immune
function (Table 1) [15]. Deficiencies and/or inadequate status in these nutrients may negatively affect
immune system, resulting in decreased resistance against infections.
Table 1. Recommended intakes of certain nutrients with key roles in disease susceptibility and the
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DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid, RDA: Recommended Dietary Allowances.
The mentioned vitamins and minerals are essential for adaptive immunity as they are involved in
cytokine production, lymphocyte differentiation and proliferation, antibody production, and generation
of memory cells. Regarding to innate immunity, they also contribute to the maintenance and
development of physical barriers and differentiation of innate cells, production, and activity of
antimicrobial proteins, phagocytic activities of neutrophils and macrophages, and regulation of the
overall inflammatory response.
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Significant research has been conducted over decades regarding the usage of vitamin C as a remedy
for colds [3]. In the case of COVID-19, there is no evidence so far to recommend its supplementation.
In this regard, a clinical trial devoted to analyzing the effect of vitamin C (24 g/day for 7 days) in 140
patients with severe COVID-19 is being carried out in Wuhan (China) (Identifier: NCT04264533) [27].
The relationship between vitamin A and infections has been extensively described. In the case of
respiratory infections, vitamin A plays a pivotal role due to its involvement in healthy mucus layer
formation, as well as enhancing antigen non-specific immune response [28]. Indeed, histopathological
alterations have been described in pulmonary epithelium and parenchyma in subjects with vitamin
A deficiency, resulting in impaired respiratory function [29]. Consequently, adequate intakes of this
vitamin should be guaranteed in order to avoid further complications in the case of COVID-19.
The association of vitamin D deficiency with respiratory tract infections and lung injury has
been widely reported. Indeed, the usage of vitamin D agonists has shown effectiveness ameliorating
the aforementioned conditions [30]. Furthermore, previous investigations have demonstrated that
high-dose supplementation of vitamin D (250,000–500,000 IU/day) is safe and effective in improving
the health status of mechanically ventilated critically ill patients (enhancing the capacity of blood for
oxygen transport and increasing hemoglobin levels), which resulted in shorter hospital stays [31,32].
With regard to COVID-19, Ilie et al. have studied the role of vitamin D levels on the prevention of this
infection and the mortality induced by this disease [33]. The authors have determined the mean levels
of 25(OH)D in subjects from 20 European countries, as well as the number of positive cases and deaths
caused by COVID-19. They have found a negative association between the mean levels of vitamin D
and the number of COVID-19 cases, as well as with the mortality. They also observed that vitamin
D levels are severely low in the aging population, which is the most vulnerable population group
for COVID-19.
In the same line, a retrospective study carried out in Switzerland has shown that patients positive
for SARS-CoV-2 have lower levels of 25(OH)D than non-infected subjects [34]. However, when patients
were stratified by age, the mentioned difference was only significant among patients older than 70
years, who are the subjects in higher risk to suffer clinical complications in COVID-19. Based on the
results obtained, the authors proposed to reach a plasma concentration of 30 ng/mL 25(OH)D in this
population, in order to reduce the risk in case of serious disease.
Nevertheless, not all the results go in the same direction. Thus, taking into account that black
and minority ethnic individuals seem to be more affected by COVID-19, vitamin D deficiency is
being studied to explain this fact. In a study conducted by the UK Biobank, 1474 participants were
submitted to COVID-19 test, being positive 449 of them. Among the 1474 subjects, 95% were white
people (12% of them were vitamin D deficient), 1% were black people (36% of them were vitamin D
deficient), 2% were South Asian subjects (57% of them were vitamin D deficient) and the remaining 2%
belonged to other ethnic groups (29% of them were vitamin D deficient). Among all the participants,
25(OH)D concentration was lower in those patients who subsequently had confirmed COVID-19
infection. Moreover, 25(OH)D predicted COVID-19 infection when displayed an univariate analysis,
but not after it was adjusted for potential confounders. Univariate analysis showed that black and
South Asian ethnicities were associated with confirmed COVID-19 infection compared with whites,
although adjustment for 25(OH)D serum concentrations showed no significant associations between
vitamin D nutritional status, ethnicity, and an increased susceptibility to COVID-19 infection. Authors
concluded that the potential role of 25-hydroxyvitamin D concentration to explain susceptibility to
COVID-19 infection could not be supported overall or in blacks and minority ethnic populations [35].
Nevertheless, it should be highlighted that after the publication of these results, two letters to the
editor showing some weak points of this study have been published [36,37].
As shown in the previous lines, the studies carried out to date have reported controversial results
regarding vitamin D levels and the risk to develop COVID-19. Consequently, there is no enough
evidence to recommend supplementation of this vitamin in those subjects who do not exhibit deficits.
In this regard, meeting the recommended dietary allowances for this vitamin would be the best advice.
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By contrast, higher doses of vitamin D are advisable for vulnerable subjects in order to avoid deficits,
especially in situations of lockdown [3].
Vitamin E has been related to the correct function of the humoral and innate immune functions.
Indeed, the ability of vitamin E to scavenge reactive oxygen species (ROS) plays an important role
in oxidative stress reduction, exerting anti-inflammatory effects. In addition, vitamin E also protects
polyunsaturated fatty acids (PUFAs) and immune cells from oxidation. To date, there is little evidence
regarding the use and/or dosage of vitamin E as a prophylactic or therapeutic agent against COVID-19.
Iron is a nutrient with diverse implications in COVID-19. On the one hand, it is well known the
importance of iron for the correct functioning of the immune system. However, it is also well established
that iron-containing enzymes are essential for the completion of virus replication process, particularly
coronaviruses [21]. Thus, it has been pointed out that iron chelation could be an alternative adjuvant
strategy to treat COVID-19 patients, via manipulation of key iron regulators (still needs further research)
or via venous injection or oral administration of iron chelators. In this sense, previous treatments
with iron chelator deferiprone (DFP, Ferriprox®) prolonged the survival of patients with acquired
immunodeficiency syndrome (AIDS) after human immunodeficiency virus (HIV) infection [38,39].
Evidence also suggests that iron chelators can exhibit antiviral effect on HIV through the elevation of
intracellular iron efflux and increasing iron exporter ferroportin expression [40]. Despite to date little
is known about iron regulation in COVID-19 patients, it could be deduced from other viral infections
that iron chelation might be an alternative beneficial adjuvant in treating COVID-19. However, it is
important to point out that there is no empirical research to date, so further investigation is needed.
Selenium plays an essential role in the immune system due to its anti-inflammatory effect.
Zhang et al. (2020) have identified a positive association between higher recovery rate from COVID-19
infection and adequate selenium status in 17 cities outside the region of Hubei (China) [20]. This effect
is in line with the significant benefits of selenium supplementation demonstrated against other viral
infections, including HIV [41,42], hepatitis B linked liver cancer linked [43] or epidemic hemorrhagic
fever [44].
Interestingly, the amount of trace elements present in food varies according to the geographical
differences of the soil. In this regard, soils in different regions of China have been reported to have the
highest and lowest selenium levels in the world. Zhang et al. (2020) have found that infected patients
from the areas with high selenium levels were more prone to recover from COVID-19 [20]. Indeed, the
cure rate (percentage of COVID-19 patients declared as recovered) was almost threefold higher on the
city of Enshi in Hubei Province, which has the highest selenium intake in China, compared to the other
cities in Hubei. By contrast, in Heilongjiang Province, where selenium intake is among the lowest in
the world, the death rate from COVID-19 was almost fivefold higher than the average of all the other
provinces outside of Hubei. These observations suggest that selenium intake seem to be related to the
clinical outcome in COVID-19 patients. However, further research is still needed in order to provide
more specific advice regarding the adequate intake of this mineral.
With regard to zinc, te Velthuis et al. (2010) demonstrated that increasing Zn2+ concentration
inhibits the replication of SARS-coronavirus (SARS-CoV) [45]. On the other hand, zinc deficiency
is linked with defective cell-mediated immune response, as well as with increased susceptibility for
various infections. Indeed, it has been suggested that increased zinc intake may exert beneficial effects
on COVID-19 infections by reducing gastrointestinal and lower respiratory symptoms. In addition, it
has been suggested that zinc intakes of 30–50 mg/d may exert beneficial effects on RNA viruses [46].
Copper is essential to maintain DNA integrity by preventing oxidative DNA damage. Studies
conducted in rodent models with chronic TNF-α-induced lung inflammation proposed that copper
supplementation may ameliorate such inflammation [47]. However, no substantial evidence is available
in order to recommend copper supplementation against COVID-19.
Figure 2 shows the effects of several nutrients on immune system function and other important
aspects on COVID-19 infection, such as oxidative stress, inflammation, and thrombosis.
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3. The Role of Specific Bioactive Co pounds Present in the Diet on I une Syste Function
and COVID-19 Disease
Nowadays, there is an urgent need to identify molecules effective to prevent COVID-19 disease
and/or to reduce its severity. In this regard, it has been found that several natural bioactive compounds
interact with ACE2 receptor, which is the gateway for SARS and SARS-CoV-2, and thus regulates the
viral infection. Natural bioactive compounds can also reduce the inflammatory response induced by
SARS-CoV-2 infection. Taking into account that a great number of the patients with COVID-19 present
“pro-inflammatory cytokine storm”, which drive to a worse prognosis, these molecules could represent
a promising target for immunomodulatory therapies. In the following lines, the potential benefits of
resveratrol (3,5,4′-trihydroxy-trans-stilbene), celastrol, oleoylethanolamide, and natural peroxisome
proliferator-activated receptor γ (PPAR-γ) agonists (Figure 3) are described. Nevertheless, it should be
pointed out that the vast majority of these results have been obtained in animal models; thus, further
studies are still needed to check them in humans.
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3.1. Resveratrol
Resveratrol is a polyphenol belonging to the group of stilbenes, naturally found in red wine,
berries, grapes, nuts, and other foodstuffs. Horne et al. (2020) reviewed the biological interaction
between resveratrol and the ACE2 receptor described in four studies that have been published to
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date [48]. As explained in the Introduction section, SARS-CoV-2 uses the ACE2 receptor to enter the
mammalian cells, as well as the transmembrane protease serine 2 (TMPRSS2), involved in the viral
spike-(S) protein cleavage, which in turn mediates the fusion of virus and cellular membranes necessary
for viral entry (Figure 1). Therefore, due to the role of ACE2 in SARS-CoV-2 infection, it could be
thought that nutrients or molecules (such as some bioactive compounds and antihypertensive drugs)
that may enhance the expression/synthesis of this enzyme should be avoided in order to reduce the
risk of infection. However, it must be noted that ACE2 activation also exerts beneficial effects on the
lung injury produced by SARS-CoV-2 infection [3]. Thus, due to the dual role that ACE2 may play in
COVID-19, further research is needed in order to better understand whether its activation represents a
beneficial or a detrimental effect in the development of the disease.
Tiao et al. (2018) observed, in a study carried out in rats, that resveratrol increases ACE2 protein
levels in the liver, at a dose of 50 mg/kg/day [49]. Oliveira Andrade et al. (2014) reported that mice fed
a high-fat diet supplemented with resveratrol revealed increased ACE2 gene expression in adipose
tissue compared with mice fed the high-fat diet alone [50]. Kim et al. (2018) studied the effect of this
natural compound in thoracic aortas of 24-month-old mice, observing an increased expression of ACE2
protein and an enhanced protection against arterial aging [51]. There is also an in vitro study carried
out in human aortic smooth muscle cells, in which resveratrol incubation for 24 h up-regulated ACE2
protein [52].
3.2. Celastrol
Habtemariam et al. (2020) reviewed the effect of celastrol, a pentacyclic triterpenoid, which
has shown anti-inflammatory benefits on lung diseases, in animal models, by suppressing NF-kB
signaling [53] (Figure 4). In the study reported by Shi et al. (2018), this compound improved chronic
obstructive pulmonary disease by decreasing interleukin-8 (IL-8), TNF-α, and monocyte chemoattractant
protein-1 (MCP1) levels, as well as by increasing enzymatic antioxidant defenses in mice [54]. These results
are in good accordance with those previously reported by Wei and Wang (2017), who observed that celastrol
reduced these pro-inflammatory cytokines and NF-kB activation in rats, showing lipopolysaccharide
(LPS)-induced acute respiratory distress syndrome [55]. More recently, Iwata-Yoshikawa et al. (2019)
showed that NF-kB pathway was regulated by TMPRSS2 protein in the airway of a TMPRSS2 knockout
murine model, after coronavirus infection [56]. In this sense, the authors suggested that celastrol could be
a promising candidate for COVID-19 treatment due to its capacity to inhibit TMPRSS2 protein and, thus,
reduce the cleavage of S protein and the subsequent viral entry.
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3.3. Oleoylethanolamide
It is well known that the activation of immune system receptors called toll like receptors
(TLRs) reduces the expression levels of PPARs, thus activating the NF-kB pathway and leading to
the release of cytokines IL-6 and interleukin-1β (IL-1β) [57,58]. Ghaffari et al. (2020) suggested
that oleoylethanolamide (OEA), derived from oleic acid (omega-9 monounsaturated fatty acid) and
synthesized in the gastro-intestinal tract, may activate PPAR-α receptors and thus prevent gene
expression of inflammatory cytokines [59]. This is supported by the results observed in a recent clinical
trial where OEA decreased serum levels of IL-6 and TNF-α in obese patients [60]. These facts have
encouraged the authors to conduct a clinical trial to evaluate this hypothesis on patients infected with
COVID-19 in Iran.
3.4. Natural PPAR-γ Agonists
In viral infections, pro-inflammatory cytokines (e.g., TNF-α and IL-1) are released by lung-epithelial
cells, endothelial cells and immune cells. PPAR-γ, a transcription factor member belonging to the
PPAR family, is known as a regulator of inflammatory response. It suppresses the expression of
the pro-inflammatory M1 macrophages and activates the proliferation of anti-inflammatory M2
macrophages. Moreover, it acts on the transcription of inflammatory cytokine genes and inhibits the
production of cyclooxygenase-2 (COX-2), an enzyme that induces inflammatory response [61].
In this context, natural PPAR-γ agonists present in foodstuffs could also act as anti-inflammatory
molecules by inhibiting the expression of pro-inflammatory cytokines. Ciavarella et al. (2020)
have published a review where the anti-inflammatory effect of several natural compounds are
summarized [62]: (a) EPA and DHA, provided by sea food and fish oil [63], (b) carvacrol, a monoterpenic
phenol present in thyme and oregano, two plants of the Mediterranean area [64], (c) capsaicin, contained
in hot pepper, one of the most used spices around the world [65], (d) carnosic acid and carnosol, two
dipertenoids present in rosemary and sage [66,67], (e) punicic acid, contained in pomegranate seed
oil [68], (f) citral, present in lemongrass oil [69], and (g) curcumin [70,71].
The effects of curcumin on SARS-CoV-2 infection have been addressed by several research groups.
As early as 2007, Wen et al. determined the quantity of spike proteins in cultures of Vero E6 cells
infected with SARS-CoV, and observed that this compound was able to significantly decrease the
virus replication [72]. Later on, Ting et al. (2018), using porcine epidemic diarrhea virus (PEDV) as a
coronavirus model, showed that curcumin could suppress viral replication by inhibiting the synthesis
of negative-strand RNA virus [73]. Recently, Zahedipour et al. (2020) have shown that curcumin may
target critical steps of the viral infection by reducing the penetration of the virus and attacking the
components necessary for the viral replication cycle [74].
It is important to point out that some patients infected with COVID-19 develop pulmonary fibrosis,
which is mediated by the transforming growth factor β (TGF-β) pathway. With regard to this signaling
pathway, it has been reported that curcumin induces a reduction in a mouse model of viral-induced
acute respiratory distress syndrome [75]. Moreover, curcumin can reduce type I collagen protein and
TGF-β mRNA levels in rodent models with fibrosis [76]. Although the anti-fibrotic effects of curcumin
have not been tested in a model of COVID-19, similar effects in this case may be hypothesized.
3.5. Probiotics
The gut microbiota is in continuous bidirectional interaction with the host, regulating both adaptive
and innate immune systems. It is well known that alterations in intestinal microbiota composition and
its metabolites influence organs involved in metabolism, such as adipose tissue or liver, producing
metabolic inflammation [77]. Nowadays, great attention is paid to the presence of microorganisms
in the lung, an organ rich in bacterial colonies. Indeed, a crosstalk between both organs known as
“gut-lung axis” has been proposed [78]. Consequently, exogenous factors, such as antibiotics, diet, or
exposition to toxics, that alter gut microbiota, could cause lung inflammation through the mentioned
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axis, thus increasing morbidity of fibrosis or pneumonia, which are clinical outcomes of COVID-19.
Taking this into account, it has been recently postulated that probiotics can exert protection against
viral infections at three different levels: (a) providing a stronger innate immune response in the gut,
(b) decreasing the gut permeability, and (c) regulating the acquired immune response [79].
In a pilot study, fecal samples of patients diagnosed with SARS-CoV-2 infection (confirmed
via polymerase chain reaction (PCR) tests) were collected during hospitalization and compared
with samples of healthy individuals [80]. COVID-19 patients presented more opportunistic
pathogens and a depletion of commensals in the gut, while healthy subjects maintained a higher
prevalence of Eubacterium, Roseburia, Lachnospiraceae Eubacterium, Faecalibacterium prausnitzii, Roseburia,
and Lachnospiraceae. Right now, there are three registered clinical trials devoted to studying the effect of
probiotics on COVID-19 patients [79]. One of them is a preventive study that evaluates the beneficial
effects of Lactobacillus coryniformis on the incidence of COVID-19 illness in healthcare workers exposed
to SARS-Cov-2 (NCT04366180). Other clinical trial is evaluating the effect of bacteriotherapy in the
treatment of patients with acute diarrhea, and in the prevention of intensive cares in COVID-19 patients
(NCT04368351). In the third one, the adjuvant use of oxygen-ozone therapy, along with probiotic
supplementation, is investigated in patients with COVID-19 (NCT04366089).
Based on these ideas, probiotics could be proposed as potential tools to be included in the
nutritional treatment of COVID-19 patients. Thus, Renzo et al. (2020) have suggested the potential
therapeutic use of probiotics such as Lactobacillus rhamnosus and Bifidobacterium lactis, which exhibit
anti-inflammatory effects, and prebiotics for restoring the innate and adaptive immunity [81].
4. Protein-Energy Malnutrition
When addressing COVID-19 disease, the study of nutritional status is very relevant since it plays
an important role on the functionality of immune system, necessary to face the virus infection. Indeed,
malnutrition is associated with immune dysfunction and thus it is likely to assume that this condition
could make individuals more vulnerable to the viral infection [82,83].
On the other hand, nutritional status can be negatively affected by the SARS-CoV-2 itself, as well
as by the applied treatments. Hospitalized patients with COVID-19 tend to present malnutrition at
the time of hospitalization. Chronic diseases that are commonly present in patients with COVID-19
(mainly diabetes, chronic obstructive pulmonary disease, renal insufficiency, cardiovascular diseases or
dementia), as well as other risk factors such as socio-economic status or frailty, have negative effects on
the nutritional status of these patients. In addition, during hospital stay, the prolonged immobilization,
mainly in long stays in intensive care units (ICU), leads to muscle mass losses, making the recovery of
these subjects harder. Furthermore, the need for assisted breathing during prolonged periods also
contributes to the development of sarcopenia and malnutrition [84–88]. This deteriorated nutritional
status seems to be involved in the virulence of the virus, and probably in the clinical outcome. In this
regard, studies conducted in Italy have demonstrated the importance of maintaining/recovering an
adequate nutritional status in the clinical outcomes of the patients [89,90].
Due to fluid administration and rapid wasting of lean tissues, weight and BMI changes do not
accurately reflect malnutrition in COVID-19 patients. Thus, the loss of lean body mass is of more
concern than that of the BMI. Indeed, loss of muscle and sarcopenia have to be detected, since the
larger the muscle mass decrease is, the more severe the malnutrition will be [91].
Malnutrition is probably due to anorexia, nausea, vomiting, and diarrhea (which impair food
intake and absorption), hypoalbuminemia, hypermetabolism, and excessive nitrogen loss [92,93].
These effects are clearly associated with the increase in pro-inflammatory cytokines observed in
these patients. Moreover, anorexia can also be related to dysgeusia. Lechien et al. conducted a
study devoted to analyzing the effect of COVID-19 infection on gustatory disorders [94]. For this
purpose, 417 mild-to-moderate COVID-19 patients (164 males and 263 females) with a mean age of
37 years old were recruited from 12 European hospitals. More than 88% of the patients reported
gustatory dysfunction, which was characterized by impairment of salty, sweet, bitter, and sour tastes.
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The gustatory disturbance consisted of reduced/discontinued or inaccurate capability to taste flavors
in 79% and 21% of patients, respectively. In these subjects, olfactory and gustatory dysfunctions
were positively correlated. In summary, this study identified gustatory dysfunction as symptom of
the European COVID-19 infection. In addition, Zayet et al. (2020) carried out a retrospective study
in 217 adults in France, where patients were divided in 2 groups: patients infected by COVID-19
confirmed by a positive PCR on nasopharyngeal sample (95 patients) and patients with a negative
PCR result on nasopharyngeal sample (122 patients) [95]. In patients positive in COVID-19, 65% had
dysgeusia, whereas in patients negative in COVID-19, only 16% had this symptom. This difference in
the frequency was statistically significant. The authors concluded that dysgeusia is frequently reported
in patients consulting from COVID-19. Other authors also showed similar results [96–99]. It is still
unknown the mechanism by which gustatory dysfunction takes place, but according to Printza et al.
(2020), SARS-CoV-2 may enter into tongue taste cells via the ACE-2 receptor, which not only is present
in pulmonary tissue but also in taste organs (at least in mice) [100]. Accordingly, the usual function of
the sensory cells can be disturbed.
Several studies have shown the results of nutritional status assessment in various cohorts of
COVID-19 patients. Li et al. (2020) carried out the first study aimed to evaluate the nutritional status
in elderly patients suffering COVID-19 [101]. For that purpose, a cross-sectional study was designed
including 182 patients (65 male and 117 female) from a hospital in Wuhan (China), with a mean age of 69
years and positive in COVID-19. The nutritional assessment of the participants was performed by using
the Mini Nutritional Assessment (MNA), a tool for institutionalized geriatric patients. MNA takes into
account food intake, weight loss, BMI, morbidity, major or acute psychological diseases, and cognitive
status. In these patients, MNA mean score was 22.9, which means a risk of malnutrition; in fact, among
the patients, 53% were malnourished, 28% at risk of malnutrition and 20% non-malnourished. There
were no differences in age, gender, triceps skin-fold thickness, mid-arm circumference, hypertension,
or cerebrovascular, cardiovascular, and chronic lung diseases among the three groups. However, there
were statistical differences in the incidence of diabetes mellitus, BMI, calf circumference, albumin,
hemoglobin, and lymphocyte counts among the three groups, being the highest values in the group
without malnutrition and the lowest in malnourished group. Finally, the multivariate regression
analysis showed that diabetes, low calf circumference, and low albumin levels were independent risk
factors for malnutrition in these subjects. In view of these results, the authors concluded that in Wuhan
(China) there was a high prevalence of malnutrition in elderly patients with COVID-19.
Liu et al. (2020) aimed to evaluate the nutritional risk, as well as their associated clinical outcomes,
in older patients with COVID-19. To do so, a retrospective study was carried out in 141 patients (68
males and 73 females), older than 65 years (average age 72 years), 77 of them with hypertension or/and
diabetes, showing different status of COVID-19 (46 common COVID-19, 73 severe COVID-19 and
22 extremely severe COVID-19), treated in a hospital from Wuhan (China) [102]. Participants were
classified as normal group (no nutritional risk) or as nutritional risk group, according to the criteria
of each nutritional risk tool used. The nutritional screening risk methods used by researchers were
Nutrition Risk Screening 2002 (NRS 2002), Malnutrition Universal Screening Tool (MUST), MNA short
form (MNA-sf), and Nutrition Risk Index (NRI). NRS 2002 predicts patients who would benefit from
nutritional treatment in hospital settings and takes into account the BMI, body weight loss, food intake
and the severity of the disease. MUST is useful for identifying the necessity of nutritional treatment
and for assessing the risk of malnutrition based on different factors like BMI, unintentional weight loss
and the presence of acute disease factors to detect disease related malnutrition. NRI is a screening tool
that predicts patient’s malnutrition status, based on serum albumin, as well as, on current and usual
body weight.
Depending on the used nutritional screening risk method, the assignation to each tool to normal or
nutritional risk groups was as follows: 85% of the patients with NRS 2002, 41% with MUST, 77% with
MNA-sf and 60% with NRI were assigned to the risk group. These results show that, independently of
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the used nutritional assessment method, a high percentage of the older patients suffering COVID-19
showed malnutrition.
As far as anthropometric measurements and clinical outcomes are concerned, statistical analysis
did not show differences between the normal group and the nutritional risk group. By contrast, with
MUST tool BMI was lower in nutritional risk group than in normal group. When using NRS 2002, the
fever duration was measured, which resulted to be longer in the nutritional risk group when compared
to the control group. Serum albumin and total protein levels were also higher in the control group
than in the nutritional risk group, by using all the nutritional risk tools, with the exception of MUST.
When data were adjusted for age, sex, presence of co-morbidities and BMI, NRS 2002, MNA-sf,
and NRI methods demonstrated that patients from the nutritional risk group showed longer hospital
stay, lower appetite, worse severity of the disease, and greater weight loss than the patients in the
normal group. By using NRS 2002 and NRI methods, patients with nutritional risk also showed higher
hospital expenses than normal patients.
5. Recommendations for Nutritional Treatment
Although nowadays, the knowledge regarding the nutritional support during hospital stay of
COVID-19 patients is still limited, nutritional therapy appears as first-line treatment and should
be implemented into standard practice [7,103,104]. In spite of that, due to the priority assigned to
urgent pathologies like respiratory issues, the nutritional status of patients has been relegated to a
second place. In fact, almost half of the hospitalized polymorbid and 23–60% of patients in acute care
are not correctly nourished [105,106]. Other facts that have also exacerbated this situation are that
medical teams cannot invest enough time to grant an optimal nourishment due to work overload,
staff shortages (healthcare personnel have suffered a high infection rate) or insufficient availability of
personal protective equipment. Additionally, a restriction to family visits has been applied in most
affected countries, removing a support in nourishment. Moreover, in most hospitals clinical teams and
structures have been reorganized resulting in provisional limitations of dietetic support.
The general recommendation for COVID-19 patients is to follow healthy diets to maintain a
correct immune function [3]. Optimal intake of all nutrients, mainly those that play crucial roles
in immune system, should be assured through a diverse and well-balanced diet. However, current
data suggest that there is a prevalent micronutrient and omega-3 fatty acid deficiency in several
population groups [107–109]. On the other hand, in the review reported by Calder et al. (2020) [16],
based on several meta-analysis [110–118], the authors state that in order to promote the optimum
functioning of the immune system and to reduce the risk and consequences of infections, the intakes
for some micronutrients may exceed the recommended dietary allowances since infections and other
stressors can reduce micronutrient status. Thus, supplements may help restoring their normal blood
levels [16,119–121]. With regard to supplementation, it is important to advise the general public
to always consult a medical doctor prior consuming such products, as they can interact with other
nutrients, drugs, and medical treatments; indeed, they can turn into toxic elements causing several
disorders and aggravating certain conditions.
5.1. Nutritional Therapy in Non-Critically Ill Hospitalized COVID-19 Patients
Cintoni et al. (2020) described the nutritional management strategy adopted in Fondazione
Policlinico A. Gemelli-IRCCS (Rome, Italy), which is considered a reference center for COVID-19 in the
region [122]. Due to the mean age of their patients (65 years), their nutritional status is usually not
optimal. Moreover, the low palatability of hospital meals makes the energy and protein intake low,
which can exacerbate the bad nutritional status of the patients. In this scenario, the orally feedable
patients of COVID-19 receive a personalized meal provision, which is completed with oral nutritional
supplements in order to meet the energy and protein requirements. In the case of patients who are
unable to eat, enteral/parenteral nutritional formulas, rich in protein and poor in glucose, are provided.
In this regard, previous studies conducted in China have demonstrated that the inclusion of nutritional
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support in the treatment of symptomatic COVID-19 patients is of major importance. The conclusion of
these studies is that the design of specific nutritional strategies are needed in hospitals [123].
Caccialanza et al., (2020) have also proposed an empirical protocol to promptly and pragmatically
implement nutritional care in hospitalized non-ICU COVID-19 patients [89]. The authors recognized
that their protocol might be debatable, since it may not be in total agreement with the current
guidelines on clinical nutrition [124]. However, they do believe that nutritional care in hospitalized
non-ICU COVID-19 patients might be overlooked despite being potentially effective in preventing
the consequences of malnutrition and beneficial to clinical outcomes in this patient population [89].
The authors have based their protocol on the observation of the symptoms shown by the patients
at hospital admission (severe inflammation, anorexia leading to a major reduction of food intake,
and respiratory failure). Since a significant number of patients reported severe eating difficulties,
they decided to start with an oral supplementation with whey proteins (20 g/d) and intravenous
multivitamin, multi-mineral, and trace element solutions, in order to match the recommended dietary
allowances upon admission. Whey proteins were selected based on their high digestibility, anabolic
and antioxidant properties [125], immunomodulatory [126], and potential antiviral activities [127].
Further, since specific vitamin and micronutrient deficits have been reported to be harmful during
viral infections, including COVID-19 patients [7], the authors justify the micronutrient intravenous
administration to meet recommended dietary allowances. The most debatable aspect of their protocol
might be the election of parenteral nutrition over enteral nutrition. This election is due to the
respiratory difficulties of COVID-19 patients. Certainly, enteral nutrition requires the presence of a
nasogastric tube, which may compromise the effectiveness of non-invasive ventilation or continuous
positive airway pressure [89]. Further, enteral feeding implies an increased risk of aspiration of the
nutritional solution [128]. Indeed, this protocol shows debatable limitations, but taking into account
that underfeeding occurs in patients hospitalized for COVID-19, a rapid intervention in non-critically
ill patients can improve their prognosis, therefore reducing the pressure on the limitation in ICU
availability detected in hospitals worldwide [129].
Once the acute phase of the pneumonia is over, COVID-19 patients need specific rehabilitation, not
only to recover the respiratory capacity but also to improve disability and quality of life. Brugliera et al.
(2020) describe their experience working in the COVID-19 rehabilitation unit in the Hospital of
San Raffaele Scientific Unit (Milan, Italy) with 50 COVID-19 patients [6]. According to the authors, the
majority (90%) of the patients showed some degree of dysphagia, mainly due to previous orotracheal
intubation, making necessary the use of diets with modified consistency or nasogastric feeding,
and highlighting the importance of nutritional support, as well as of swallowing training to improve
the recovery of these patients. Due to the direct relationship between nutritional status and the risk of
suffering from different illnesses (among them the COVID-19), this parameter was studied by means of
the MUST, and the results showed that 45% of the studied population were in high risk of malnutrition,
while 26% had moderate risk.
Based on the knowledge acquired by the authors while working with patients who were recovering
from COVID-19, a 3-step nutritional protocol has been designed. The first step of this protocol would
be focused on the nutritional assessment and malnutrition screening of the patient. For this purpose,
different anthropometric parameters, as well as the body composition of the patients are studied.
Further, the weight loss is monitored and a hematochemical analysis of blood parameters (including,
among others, blood count, total protein, ferritin, blood sugar and markers of liver function) carried
out. Finally, the swallowing capacity of the patients (in order to determine whether a specific diet
is needed) is evaluated and their intake assessment monitored. Once this first step is completed, a
second step devoted to setting the nutritional treatment of the patient takes place. In this regard,
the energy and macronutrient requirements of the patient are assessed, using the meal management
computerized system of the hospital. In this scenario, energy requirements are calculated using
predictive equations, which are adapted to the nutritional status of the patients (clinical status, physical
activity, or stress). As far as macronutrients are concerned, a protein intake of >1 g/kg/day (up to
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1.5 g/kg/day) is guaranteed, as well as carbohydrate and lipid requirements stablished based on the
non-protein energy (30:70 in patients with no respiratory insufficiency and 50:50 in patients with
respiratory insufficiency). In addition, maintaining an adequate hydration of the patient is another
aspect of the intervention that must be taken into account. In this regard, the clinical history of the
patient (heart or renal failure, vomiting or diarrhea) must be analyzed. Moreover, additional supportive
therapy (adequate vitamin and oligoelement intake, essential and branched amino acids and probiotics)
is also provided. Similarly, nutritional advice that can be useful for the patient (while in the hospital as
well as once they are discharged) is provided. As far as the third step is concerned, this is based in
continuous monitoring of the patient by a multidisciplinary team over time, which allows modifying
the treatment according to the status of the patient.
Using this protocol, the MUST improved in 5 of the 32 patients (out of the 50 patients that were
included in the rehabilitation unit) that stayed at least for 10 days in the COVID-19 rehabilitation
unit. Moreover, 14 of these patients improved their BMI while in 15 patients this parameter remained
stable. Based on these observations, the authors conclude that nutritional status plays a pivotal role in
the clinical outcomes of patients recovering from COVID-19, and that nutritional support along with
rehabilitation may improve the chances of recovery in patients of COVID-19.
5.2. Nutritional Therapy in Critically Ill Hospitalized COVID-19 Patients
Some COVID-19 patients experience severe respiratory symptoms and/or multi-organ failure,
being very ill at hospital admission and thus needing specialized support [99,123]. Indeed, acute
respiratory complications, requiring prolonged ICU stays, are a major cause of morbidity and mortality
in COVID-19 patients. Most of these patients rapidly progress from cough to dyspnea, and then
to respiratory failure requiring mechanical ventilation. Consequently, the timing of nutritional
intervention appears to be critical [130]. Therefore, nutritionists should choose the most appropriate
way to recover the subject’s health.
As with any other critically ill patients, nutritional management is an integral component of
good supportive care. The European Society for Clinical Nutrition and Metabolism (ESPEN) has
recently published some guidelines for the nutritional management of patients with SARS-CoV-2
infection. In these guidelines specific recommendations are included for patients hospitalized in ICUs,
among them early enteral nutrition (when possible), use of agents that promote gastric emptying,
initiation of peripheral nutrition in situations in which enteral nutrition is not possible/tolerated and
use of enteral nutrition after extubation when oral feeding is not tolerated. According to these ESPEN
guidelines, enteral nutrition is preferred for patients in the ICU who receive mechanical ventilation [91].
However, the specific needs of patients with COVID-19 may require the adoption of prone ventilation
or neuromuscular blockade, and consequently enteral nutrition implementation in daily practice
could be difficult [128]. Further, a delay of enteral nutrition can be mandatory when life-threatening
hypoxemia occurs [91].
On the other hand, the changes induced by the disease itself in the gastrointestinal tract of the
patients, along with the elevated sedation required for these patients, makes difficult to provide
adequate nutritional support. Bearing this in mind, Arkin et al. (2020) provided information regarding
several of the considerations that have to be taken into account when nutrition is provided to critically
ill patients of COVID-19 [131]. One such consideration is related to the gastrointestinal hypomotility
that is commonly found in these patients, which in turn results in enteral feeding intolerance. Indeed,
this situation seems not to be derived from the high-doses of sedatives and opioids that are needed
to facilitate mechanical ventilation, since other patients under similar conditions do not present
feeding intolerance. Thus, the authors suggest that the enteral feeding intolerance is related to the
infection produced by the SARS-CoV-2. Moreover, despite several pharmacological agents devoted to
promoting gastrointestinal motility are provided to COVID-19 patients at the time of ICU admission,
their intestinal motility remains impaired. Additionally, even in the cases in which gastrointestinal
motility is maintained/recovered (by studying gastric residuals and stool output), impaired nutrient
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absorption has been described. In the case of the patients in which gastric residuals are >500 mL, the
use of a post-pyloric feeding tube is recommended by the ESPEN guidelines. However, this approach
involves technical challenges in the placement as well as increased exposure of the staff to viral infection
and obvious difficulties when proning of the patient is required. Besides the gastrointestinal features
of critically ill COVID-19 patients, severe lung injury is also common in these subjects. This condition
makes necessary strategies devoted to avoiding aspirations. In this regard, the authors suggest holding
tube feeding 1-h prior proning as an effective approach to avoid aspirations. Indeed, the authors state
that due to the challenges related to aspiration in prone patients, continuous tube feeding is maintained
(instead of using bolus tube feeding).
As far as diet is concerned, the ESPEN guidelines recommend hypocaloric nutrition in the first
week of ICU stay. However, since the patients normally spend days/weeks sick at their homes
before being admitted in a hospital, the risk of developing malnutrition increases. Moreover, the
life-threatening features that are common on these patients at the time of ICU admission produces
further delay in enteral nutrition, increasing even more the risk of malnutrition. Due to these facts,
critically ill COVID-19 patients may have poor nutritional status, which in turn may increase the
severity of the infection. In this regard, the authors point towards the necessity of a more aggressive
early total parenteral nutritional support in these patients.
Taking all that into account, and considering that COVID-19 patients need more energy than normal,
the nutritional management of the critically ill patient in the long-term should avoid underfeeding or
overfeeding. It is recommended to supply around 20 or 30 kcal/kg body weight/day for polymorbid
patients aged >65 years or for severely underweight polymorbid patients respectively [124,132]. These
values should be adjusted with regard to nutritional status, disease status, and tolerance [133]. It is
important to take into account that in severely underweight patients, the target of 30 kcal/kg body
weight/day should be slowly achieved (in the case of artificial nutrition, target speed must be reached
in 3–4 days) due to the high risk of refeeding syndrome of this population [104,132].
Protein needs are higher in the critically ill patient due to the protein catabolism driven by
inflammatory mediators [132]. It is estimated as 1 g protein/kg body weight/day in older people [133],
or 1.3 g protein/kg body weight/day with increased supply of branched chain amino acids (up to
50% in polymorbid medical inpatients), in order to prevent muscle loss and to strength respiratory
muscles [132]. Other authors increased these recommendations to 1.5 g protein/kg body weight/day [89]).
These amounts should be individually adjusted with regard to nutritional status, disease status,
and tolerance [124].
The needs of fat and carbohydrate have to be adapted to the energy requirements, considering an
energy ratio from fat and carbohydrates between 30:70% for individuals with no respiratory deficiency
and to 50:50% for ventilated patients [104]. Fat requirement in the critically ill patient is around
1.5 g/kg body weight/day, giving priority to the usage of medium and long chain fatty acids. As far as
carbohydrates requirement is concerned, a supply of 2 g/kg body weight/day, not exceeding 150 g/day,
must be considered. This is due to their high CO2 production rate that should be limited in case of
respiratory failure [132].
With regard to micronutrients in ICU patients, mineral and vitamin supply with routine
supplements must be considered depending on the nutritional therapy used. Administration of
doses higher than recommendations of vitamin D can be used because of their positive effects [132].
Certainly, it has been reported that high doses of Vitamin D in infected patients may improve
immunologic recovery during antiretroviral treatment, reduce levels of inflammation and immune
activation, and increase immunity against pathogens [89]. In turn, vitamin C supplementation
significantly reduces mortality in critically ill patients [134].
In the case of enteral nutrition, attention must be paid to the needs of specific nutrients to be
included in the formula. Thus, enteral diets containing EPA, gamma-linolenic acid, and antioxidant
agents may offer a clinical benefit in oxygenation and days of ventilation in patients with acute
respiratory distress syndrome [91]. Further, specific lipid emulsions could offer additional benefits
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over corticosteroid and anti-IL-6 drugs in the modulation of the inflammatory response. However,
COVID-19 patients’ response to specific enteral diets remains to be determined [130].
6. Future Research
In the present review, we provide data about key aspects in nutritional management of COVID-19
patients, based on the current knowledge. Nevertheless, due to the novelty of the disease, information
regarding the effects of some nutrients is still scarce.
Regarding the role of specific nutrients in COVID-19 disease, very often the nutritional advice is
based on their effects in infections caused by other viruses with symptoms similar to those caused
by SARS-CoV-2. On the other hand, in some cases the studies reported are ecological studies, which
are the first step in the investigation of a possible relationship between a disease and a determined
exposure. Their great advance is that they are carried out very quickly, practically without cost and with
information that is usually available. However, their main limitations are that they cannot determine
if there is an association between an exposure and disease at the individual level, and their inability
to control for potentially confounding variables. Consequently, further research based on analytical
instead of descriptive studies, such as randomized controlled clinical trials, are warranted.
Regarding the effects of bioactive compounds present in foodstuffs on COVID19, the vast majority
of the results have been obtained in preclinical studies. One advantage of these studies is that animals
can be directly exposed to the virus under treatments with various bioactive compounds, as a first step
to know if some of these substances could reduce or even prevent infection with the SARS-CoV-2 virus.
Moreover, they allow the researchers to determine the mechanism involved. In this field of research,
studies addressed in humans are needed to confirm the beneficial effects observed in animals.
Another important aspect is to focus the research on specific age groups, paying special attention
to the elderly, since it is known that the evolution of the disease depends largely on age. In the same
way, it would be important to carry out separate studies in men and women since it appears that
men are more negatively affected by this disease. All this will contribute to making a personalized
nutritional approach, and therefore more successful.
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